A natural history study of medical cannabis consumption in pediatric autism in the United States / Mary Ann DILIBERTO in Research in Autism Spectrum Disorders, 96 (August 2022)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 96 (August 2022) . - 101994 Titre : A natural history study of medical cannabis consumption in pediatric autism in the United States Type de document : Texte imprimé et/ou numérique Auteurs : Mary Ann DILIBERTO, Auteur ; Athena F. ZUPPA, Auteur ; Amanda CORNETTA, Auteur ; Walter FAIG, Auteur ; Tryce SCULLY, Auteur ; Amanda BENNETT, Auteur ; Meghan THOMAS, Auteur ; Elizabeth WARD, Auteur ; Stephen BARR, Auteur ; Benjamin E. YERYS, Auteur Article en page(s) : 101994 Langues : Anglais (eng) Mots-clés : Marijuana  Treatment  Alternative medicine  Children  Youth Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder is specifically approved for medical cannabis consumption in 20 U.S. states, the District of Columbia, and the Territory of Puerto Rico. Despite increased access, there is limited knowledge about who consumes medical cannabis, what they consume, and perceived effectiveness. We addressed these gaps by conducting a natural history study of medical cannabis consumption. Method Children and their families engaged with a large pediatric care system were recruited to complete a telephonic study regarding their medical cannabis consumption. All children had to be consuming approved medical cannabis products issued from a state that had legalized medical cannabis for the treatment of ASD or related behaviors (irritability, hyperactivity, anxiety) (N = 89). Results The sample?s ?level of support? and gender-ratio reflected the general autism population (~33 % requiring ?Very Substantial Support? and ~80 % male). The most common treatment targets were ASD behaviors (repetitive behaviors) and irritability. More children consumed compounds with high cannabidiol (CBD) and low or no tetrahydrocannabinol (THC). While dose did not affect overall perceived effectiveness, compounds with high-levels of CBD and low-levels of THC (CBD-dominant) were perceived as more effective than CBD-only. Conclusions This ?real world? study revealed that medical cannabis is being used to treat a wide range of behaviors. Our study also suggests that children consume CBD-rich products, and the effectiveness of CBD-dosing may be tied to the inclusion of THC in the compound. Future research should evaluate optimal dosing with a particular focus on the CBD-to-THC ratio. En ligne : https://doi.org/10.1016/j.rasd.2022.101994 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=480 [article] A natural history study of medical cannabis consumption in pediatric autism in the United States [Texte imprimé et/ou numérique] / Mary Ann DILIBERTO, Auteur ; Athena F. ZUPPA, Auteur ; Amanda CORNETTA, Auteur ; Walter FAIG, Auteur ; Tryce SCULLY, Auteur ; Amanda BENNETT, Auteur ; Meghan THOMAS, Auteur ; Elizabeth WARD, Auteur ; Stephen BARR, Auteur ; Benjamin E. YERYS, Auteur . - 101994. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 96 (August 2022) . - 101994 Mots-clés : Marijuana  Treatment  Alternative medicine  Children  Youth Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder is specifically approved for medical cannabis consumption in 20 U.S. states, the District of Columbia, and the Territory of Puerto Rico. Despite increased access, there is limited knowledge about who consumes medical cannabis, what they consume, and perceived effectiveness. We addressed these gaps by conducting a natural history study of medical cannabis consumption. Method Children and their families engaged with a large pediatric care system were recruited to complete a telephonic study regarding their medical cannabis consumption. All children had to be consuming approved medical cannabis products issued from a state that had legalized medical cannabis for the treatment of ASD or related behaviors (irritability, hyperactivity, anxiety) (N = 89). Results The sample?s ?level of support? and gender-ratio reflected the general autism population (~33 % requiring ?Very Substantial Support? and ~80 % male). The most common treatment targets were ASD behaviors (repetitive behaviors) and irritability. More children consumed compounds with high cannabidiol (CBD) and low or no tetrahydrocannabinol (THC). While dose did not affect overall perceived effectiveness, compounds with high-levels of CBD and low-levels of THC (CBD-dominant) were perceived as more effective than CBD-only. Conclusions This ?real world? study revealed that medical cannabis is being used to treat a wide range of behaviors. Our study also suggests that children consume CBD-rich products, and the effectiveness of CBD-dosing may be tied to the inclusion of THC in the compound. Future research should evaluate optimal dosing with a particular focus on the CBD-to-THC ratio. En ligne : https://doi.org/10.1016/j.rasd.2022.101994 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=480

---

1 (1 - 1 / 1)